The Chemours Company (NYSE:CC) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts rate Chemours “Moderate Buy”: Of 12 covering brokerages, six recommend buying, one recommends a strong buy, four advise holding and one rates the stock a sell. The average 12-month price target is $24.10 versus a recent price of $17.25.
• Recent analyst actions were generally positive, including upgrades and higher price targets from Zacks Research, RBC and Truist, although JPMorgan maintained a neutral view and Weiss Ratings reiterated a sell rating.
• Chemours beat first-quarter EPS expectations by $0.10, reporting $0.05 per share, while revenue reached $1.38 billion. Investors are awaiting the company’s second-quarter 2026 results, scheduled for release after the market closes on August 4.

Shares of The Chemours Company (NYSE:CC - Get Free Report) have received an average rating of "Moderate Buy" from the twelve brokerages that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, four have issued a hold recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $24.10.

CC has been the subject of several analyst reports. Zacks Research raised Chemours from a "hold" rating to a "strong-buy" rating in a report on Tuesday, July 21st. Weiss Ratings reissued a "sell (d)" rating on shares of Chemours in a report on Friday, July 17th. Royal Bank Of Canada raised their price target on Chemours from $26.00 to $29.00 and gave the stock an "outperform" rating in a research report on Monday, May 11th. JPMorgan Chase & Co. boosted their price target on Chemours from $17.00 to $22.00 and gave the company a "neutral" rating in a research note on Thursday, May 21st. Finally, Truist Financial upped their price objective on shares of Chemours from $27.00 to $30.00 and gave the stock a "buy" rating in a research report on Tuesday, April 28th.

Chemours News Summary

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Zacks Research upgraded Chemours (CC) from Hold to Strong Buy, signaling stronger confidence in the company’s outlook. 3 Stocks Worth Buying After Recent Broker Ratings Upgrade
• Positive Sentiment: Analysts also raised longer-term earnings forecasts, including FY2028 EPS to $2.38 from $2.36, suggesting better profit potential over time.
• Positive Sentiment: Zacks lifted its Q4 2027 EPS estimate to $0.53 from $0.50 and increased its Q2 2028 estimate to $0.61 from $0.60, reinforcing a more constructive view on future performance.
• Neutral Sentiment: Chemours announced it will release second-quarter 2026 results after the market closes on August 4, which keeps investors focused on the upcoming earnings report. Chemours Announces Dates for Second Quarter 2026 Earnings Release and Webcast Conference Call
• Negative Sentiment: Zacks trimmed its Q1 2027 EPS estimate to $0.39 from $0.41 and Q3 2027 to $0.56 from $0.57, showing that not all near-term expectations are improving.

Institutional Trading of Chemours

Several large investors have recently made changes to their positions in CC. Atlas Capital Advisors Inc. acquired a new position in Chemours during the fourth quarter valued at approximately $26,000. Aster Capital Management DIFC Ltd acquired a new stake in shares of Chemours in the 4th quarter valued at $28,000. Covestor Ltd boosted its holdings in shares of Chemours by 204.7% in the 4th quarter. Covestor Ltd now owns 2,602 shares of the specialty chemicals company's stock valued at $31,000 after purchasing an additional 1,748 shares in the last quarter. Eurizon Capital SGR S.p.A. acquired a new stake in shares of Chemours in the 4th quarter valued at $31,000. Finally, Rothschild Investment LLC increased its stake in shares of Chemours by 87.0% in the 4th quarter. Rothschild Investment LLC now owns 2,698 shares of the specialty chemicals company's stock valued at $32,000 after purchasing an additional 1,255 shares during the last quarter. Institutional investors and hedge funds own 76.26% of the company's stock.

Chemours Stock Up 0.2%

Shares of CC opened at $17.25 on Monday. The company has a current ratio of 1.82, a quick ratio of 0.87 and a debt-to-equity ratio of 18.98. Chemours has a 12 month low of $10.44 and a 12 month high of $28.67. The firm's 50 day moving average is $20.35 and its 200-day moving average is $19.92. The stock has a market capitalization of $2.59 billion, a PE ratio of -6.53 and a beta of 1.41.

Chemours (NYSE:CC - Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The specialty chemicals company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.10. The business had revenue of $1.38 billion during the quarter, compared to analysts' expectations of $1.40 billion. Chemours had a positive return on equity of 52.49% and a negative net margin of 6.82%.The firm's revenue for the quarter was up 1.0% compared to the same quarter last year. During the same period in the previous year, the company posted $0.13 earnings per share. Equities research analysts forecast that Chemours will post 1.18 EPS for the current year.

Chemours Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 16th. Stockholders of record on Sunday, May 17th were given a $0.0875 dividend. The ex-dividend date was Friday, May 15th. This represents a $0.35 annualized dividend and a dividend yield of 2.0%. Chemours's payout ratio is presently -13.26%.

Chemours Company Profile

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours' principal business activities are organized into three core segments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.